Cellectar Biosciences shared its third quarter 2026 results and plans for a Phase 3 trial of iopofosine I 131.

Nov 10, 2026, 10:57 AM ETResultsRead the original at globenewswire.com

Good for CLRB

Updated drug data support Cellectar's planned FDA path, and one published case showed a response lasting over 8 years. The confirmatory trial and FDA filing are still ahead, so the treatment has not won approval.

CLRB · Cellectar Biosciences

AI read · Good for CLRB

The AI's read

These updates give Cellectar more support for pursuing FDA review. The company plans to start a confirmatory trial and file for review, but neither step has happened yet. The long response came from one patient. It adds evidence for the drug, but does not show how it will work for other patients.

Get alerts for CLRB

Follow Cellectar Biosciences (CLRB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLRB

Free on the App Store and Google Play, or on the web.